참고문헌
- Livingston RB. Current management of unresectable nonsmall cell lung cancer. Semin Oncol 1994;21(5 Suppl 10):4-11.
- Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. https://doi.org/10.1056/NEJMoa011954
- Sekine I, Saijo N. Novel combination chemotherapy in the treatment of non-small cell lung cancer. Expert Opin Pharmacother 2000;1:1131-61. https://doi.org/10.1517/14656566.1.6.1131
- Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3018. https://doi.org/10.1200/JCO.1997.15.8.2996
- Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39. https://doi.org/10.1056/NEJMoa1507643
- Peters S, Gettinger S, Johnson ML, Janne PA, Garassino MC, Christoph D, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed deathligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol 2017;35:2781-9. https://doi.org/10.1200/JCO.2016.71.9476
- Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-33. https://doi.org/10.1056/NEJMoa1606774
- Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced nonsmall-cell lung cancer previously treated with platinumcontaining chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-62. https://doi.org/10.1200/JCO.2000.18.12.2354
- Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-63. https://doi.org/10.1200/JCO.2006.06.1044
- Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103. https://doi.org/10.1200/JCO.2000.18.10.2095
- Bansal P, Osman D, Gan GN, Simon GR, Boumber Y. Recent advances in targetable therapeutics in metastatic non-squamous NSCLC. Front Oncol 2016;6:112.
- Kudo S, Hino M, Fujita A, Igarashi T, Arita K, Niitani H, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with non-small cell lung cancer. Gan To Kagaku Ryoho 1994;21:2617-23.
- Hainsworth JD, Burris HA 3rd, Litchy S, Morrissey LH, Barton JH, Bradof JE, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer 2000;89:328-33. https://doi.org/10.1002/1097-0142(20000715)89:2<328::AID-CNCR17>3.0.CO;2-F
- Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of nonsmall-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004;91:1996-2004. https://doi.org/10.1038/sj.bjc.6602241
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. https://doi.org/10.1016/j.ejca.2008.10.026
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. https://doi.org/10.1002/ijc.29210
- Rossi A, Gridelli C. Chemotherapy of advanced non-small cell lung cancer in elderly patients. Ann Oncol 2006;17 Suppl 2:ii58-60. https://doi.org/10.1093/annonc/mdj925
- Lilenbaum RC. Treatment of advanced non-small-cell lung cancer in special populations. Oncology (Williston Park) 2004;18:1321-5.
- Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 2015;5:2892-911.
- Kim KS, Oh IJ, Ban HJ, Cho HJ, Kwon YS, Kim YI, et al. Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m(2) for the treatment of non-small cell lung cancer. Exp Ther Med 2012;4:317-22. https://doi.org/10.3892/etm.2012.597
- Du Z, Qing J, Ye H, Zhang Z, Lu J. Effects of weekly dose docetaxel monotherapy schedule for elderly patients with non-small cell lung cancer. Chinese-German J Clin Oncol 2009;8:9. https://doi.org/10.1007/s10330-008-0148-2
- Lilenbaum R, Rubin M, Samuel J, Boros L, Chidiac T, Seigel L, et al. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol 2007;2:306-11. https://doi.org/10.1097/01.JTO.0000263713.38826.8e
- Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34. https://doi.org/10.1093/jnci/91.19.1616
피인용 문헌
- Development and Internal Validation of a Nomogram Used to Predict Chemotherapy-Induced Neutropenia in Non-Small Cell Lung Cancer Patients: A Retrospective Cohort Study vol.13, 2019, https://doi.org/10.2147/cmar.s302722